Oncology Central

Receive updates from Oncology Central for free, starting right now.

We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.

This way you won't miss any new article from Oncology Central. Unsubscribe at any time.

Site title: Home - Oncology Central

Is this your feed? Claim it!

Publisher: Unclaimed!

Message frequency: 0.65 / day

Message History

ASCO 2026: Sacituzumab govitecan combination improves progression-free survival 2 in mTNBC2 days

Original story from the ASCO Annual Meeting Results from the global phase 3 ASCENT-04 clinical trial found that sacituzumab govitecan combined with pembrolizumab improved progre...

Read full story

ASCO 2026: Triple therapy outperforms standard treatment in EMERALD-3 hepatocellular carcinoma trial3 days

Original story from the ASCO Annual Meeting Results from the Phase 3 EMERALD-3 study found that combining the standard treatment of transarterial chemoembolization (TACE) with the i...

Read full story

ASCO 2026: Multi-selective RAS(ON) inhibitor yields unprecedented survival gains for metastatic pancreatic cancer4 days

Original story from the ASCO Annual Meeting Results from the first phase 3 trial of a RAS(ON) multi-selective inhibitor show that daraxonrasib is effective for RAS-mut...

Read full story